Gilead to pay up to $5bn for antibody-drug conjugates push

The acquisition of Munich-based biotech gives Gilead ownership of proprietary ADCs tech at a time when pharma and biotech companies are racing to secure next-generation cancer treatments.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

Closing the women's health gap offers ‘benefits for all’

7 April 2026 On World Health Day 2026, despite data trending in the right direction, systemic barriers continue to limit female inventors—and women's health is suffering.

Biotechnology

Novartis bets $2bn on biologics as Xolair patents fade

27 March 2026 The Swiss pharma giant targets next-generation anti-IgE biologics as it looks to extend its dominance in the market.

Biotechnology

mRNA litigation: Who’s winning, who’s filing, and what’s next

25 March 2026 As the world moves past the pandemic, a massive legal struggle over the future of mRNA technology is just hitting its stride. LSIPR visualises the litigation defining the next era.

More features

Closing the women's health gap offers ‘benefits for all’

Bausch reaches deal with competitor over IBS drug generic

European patent offices raise fees

UPC refuses early knockout in Illumina–Element dispute

Argentina’s patent reset: Why pharma can no longer ignore Latin America's second-largest market

IndiaMart v CDSCO: A test of intermediary liability

UPC appeals court upholds Abbott injunction in glucose monitoring patent dispute

CRISPR priority feud ends at USPTO as board reaches decision

Gilead to pay up to $5bn for antibody-drug conjugates push

More on this story

Editor's picks

Editor's picks

More features